Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis

Abstract

Background This study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (c-TACE) for treating peculiar anatomical sites of gastric cancer liver metastasis. Material/Methods Of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with DEB-TACE and 33 with c-TACE. The DEB-TACE group comprised 26 males and 9 females aged 28–75 years (56.8±6.3), and the c-TACE group included 19 males and 14 females aged 33–77 (60.2±9.4) years. Liver functions of the 2 groups were compared between pre-TACE and 1-week and 1-month after TACE. Computed tomography and magnetic resonance imaging were reexamined at 1, 3, and 6 months after TACE, and short-term efficacy was assessed based on modified response evaluation criteria in solid tumors. Results One month following DEB-TACE and c-TACE, the number of cases with objective response (OR) was 29 cases (29 out of 35 cases, 82.9%) and 20 cases (20 out of 33 cases, 60.6%) and disease control (DC) in the 2 groups was 33 cases (33 out of 35 cases, 94.3%) and 26 cases (26 out of 33 cases, 78.8%) respectively ( P =0.041, P =0.031). Alanine transaminase (ALT) and Aspartate transaminase (AST) significantly increased in the DEB-TACE and c-TACE groups 1 week later ( P <0.001). There were no serious complications in the 2 groups; incidences of nausea and vomiting were significantly lower, but instances of fever were markedly elevated in the DEB-TACE group ( P =0.023, P =0.016, respectively). Conclusions The safety, feasibility, and short-term efficacy of DEB-TACE and c-TACE in the treatment of gastric cancer liver metastasis are clear. DEB-TACE leads to less incidences of nausea and vomiting but more incidences of fever than c-TACE.

CalliSpheres® microsphere transarterial chemoembolization combined with 125I brachytherapy for patients with non–small‐cell lung cancer liver metastases

“…CSM-TACE combined with 125 I brachytherapy presented a favorable treatment response and survival as well as a satisfactory safety profile among patients with liver metastases from NSCLC after radical surgery. Both CSM-TACE and 125 I brachytherapy have been viewed as effective therapies for liver metastases (10,(13)(14)(15). It has been reported that CR, ORR, and DCR are 14.3%, 78.6%, and 90.5%, respectively, at 6 months after CSM-TACE in patients with liver metastases (13).…”

“…In the past years, conventional transarterial chemoembolization (cTACE) has been viewed as a crucial treatment for liver metastases, while its therapeutic effect remains unsatisfactory (8)(9)(10). Recently, drug-eluting bead (DEB)-TACE has drawn a lot of attention in liver metastases, among which DEB-TACE using CalliSpheres ® microspheres (the first self-developed DEB in China) exhibits satisfying efficacy and tolerable safety not only in primary liver cancer but also in liver metastases (10)(11)(12)(13). For instance, CalliSpheres ® microsphere (CSM)-TACE shows acceptable survival benefits and tolerable safety in colorectal cancer liver metastases (13).…”

“…For instance, CalliSpheres ® microsphere (CSM)-TACE shows acceptable survival benefits and tolerable safety in colorectal cancer liver metastases (13). Moreover, CSM-TACE presents a favorable treatment response and manageable adverse events in gastric cancer liver metastases (10). However, the efficacy and safety of CSM-TACE in liver metastases from NSCLC after radical surgery are unclear.…”

Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer

“…A study concluded that regorafenib combined with DEB-TACE is superior to regorafenib monotherapy when considering the response, progression-free survival (PFS), and OS [ 6 ]. DEB-TACE and c-TACE demonstrated safety, feasibility, and short-term efficacy in treating gastric cancer liver metastasis [ 7 ].…”

Efficacy and safety of transarterial chemoembolization with CalliSpheres® Microspheres in head and neck cancer

“…For instance, cTACE provides good survival benefits and possesses a favorable safety profile in hepatocellular carcinoma (10); meanwhile, it has also been reported that cTACE elicits a favorable treatment response from lung cancer patients (11). Currently, drugeluting beads TACE (DEB-TACE) is being proposed to achieve superior survival benefits in several cancers compared with cTACE, among which CalliSpheres® Microspheres (CSM) (the first microsphere product independently developed in China) can sustainedly and steadily release antitumor drugs in the tumor at high concentrations with favorable embolization efficacy (13)(14)(15). Moreover, past studies have proposed that CSM-TACE is effective and safe in treating several cancers (15)(16)(17), while its efficacy and safety in HNC are unclear.…”